Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01733940
Other study ID # 10/12
Secondary ID
Status Recruiting
Phase Phase 4
First received November 21, 2012
Last updated November 27, 2012
Start date September 2012
Est. completion date June 2013

Study information

Verified date November 2012
Source Hospital Central de la Defensa Gómez Ulla
Contact ana isabel lopez figueras, MD
Phone 0034911586958
Email alopfi1@oc.mde.es
Is FDA regulated No
Health authority Spain: Agencia Española de Medicamentos y Productos Sanitarios
Study type Interventional

Clinical Trial Summary

Introduction: The vascular catheter-related bacteremia (BRC) is a major health problem in intensive care units. The use of dressings containing chlorhexidine gluconate (CHG) can decrease the catheters colonization, closely related to infection thereof.

Objective: To determine the efficacy of the dressing "Tegaderm CHG" dressings versus "Tegaderm IV" dressings in reducing the risk of colonization of central intravascular catheters in the intensive care unit (ICU).

Methods: Randomized controlled trial with blinding professional who reviews the main outcome. The study included patients over 18 years, indicating the central intravascular catheter implantation in the ICU or in the operating room, prior informed consent. Excluding subjects with positive blood culture at the time of catheter implantation.

The estimated sample size is 398 patients, with a confidence level of 95% and a statistical power of 80%. The study protocol was approved by the ethics committee of the hospital.

Be made prospectively followed subjects from study entry until catheter removal collecting information on age, sex, APACHEII, antibiotic therapy, duration of catheter insertion site and removal, reason for withdrawal and microbiological information.

For statistical analysis, a model is adjusted multivariate logistic regression, determining the interaction of variables with the likelihood ratio test and confusion by switching between the crude and adjusted effect greater than 10%.

Results and conclusions: The recruitment has started in November 2012 and is scheduled for completion in March 2013. This study will determine whether these new dressings are effective in our environment.


Recruitment information / eligibility

Status Recruiting
Enrollment 398
Est. completion date June 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria: over 18 years, indicating the central intravascular catheter implantation in the ICU or in the operating room, prior informed consent -

Exclusion Criteria:positive blood culture at the time of catheter implantation.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Intravascular Catheter Colonization

Intervention

Device:
Application of a dressing with clorhexidine gluconate in intravascular catheters.

Application of a dressing without clorhexidine gluconate


Locations

Country Name City State
Spain Central Hospital of the Defense Madrid

Sponsors (1)

Lead Sponsor Collaborator
Hospital Central de la Defensa Gómez Ulla

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of intravascular central catheter colonization. November 2012- March 2013 Yes
Secondary Adverse effects of CHG Tegaderm ® dressings. up to 4 months Yes